Cargando…

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator

A universal calibrator for the determination of all anti-Xa inhibitors would support laboratory processes. We aimed to test the clinical performance of an anti-Xa assay utilizing a universal edoxaban calibrator to determine clinically relevant concentrations of all anti-Xa inhibitors. Following a pi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Annika, Studt, Jan-Dirk, Mendez, Adriana, Alberio, Lorenzo, Fontana, Pierre, Wuillemin, Walter A., Schmidt, Adrian, Graf, Lukas, Gerber, Bernhard, Bovet, Cédric, Sauter, Thomas C., Binder, Nikolaus B., Nagler, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297422/ https://www.ncbi.nlm.nih.gov/pubmed/37371023 http://dx.doi.org/10.3390/diagnostics13122128

Ejemplares similares

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
por: Meihandoest, Tamana, et al.
Publicado: (2022)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study
por: Sathanantham, Vepusha, et al.
Publicado: (2022)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: A prospective, multicenter, observational study
por: Nilius, Henning, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
por: Ono, Ryohei, et al.
Publicado: (2022)

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response
por: Fang, Lixin, et al.
Publicado: (2022)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB/c Mice
por: Hiramoto, Keiichi, et al.
Publicado: (2023)

Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation study
por: Nagler, Michael, et al.
Publicado: (2013)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats
por: Morishima, Yoshiyuki, et al.
Publicado: (2021)

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation
por: Lucas, Fabienne, et al.
Publicado: (2021)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Edoxaban: Minor bleeding: case report
Publicado: (2022)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
por: Nitta, Kenichi, et al.
Publicado: (2016)

Superior mesenteric vein thrombosis treated with edoxaban
por: Hashizume, Yutaka, et al.
Publicado: (2017)

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
por: Sokol, Juraj, et al.
Publicado: (2020)

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia
por: Kanamoto, Ryo, et al.
Publicado: (2020)

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban
por: Rashid, Md Abdur, et al.
Publicado: (2022)

An experiment with VM/XA share
por: Pope, B G
Publicado: (1990)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
por: Riahi, Nada, et al.
Publicado: (2023)

Marker-aided Incorporation of Xa38, a Novel Bacterial Blight Resistance Gene, in PB1121 and Comparison of its Resistance Spectrum with xa13 + Xa21
por: Ellur, Ranjith K., et al.
Publicado: (2016)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016)

Point-of-care testing of coagulation in patients treated with edoxaban
por: Härtig, Florian, et al.
Publicado: (2020)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Litlin xa ninin = Alabanzas para todos los santos /
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_9tek2a9cb5ka9q1n0vqo5de38p